Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283335 · ClinicalTrials.gov registry record · Phase 3
The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,531
- Enrollment target
NCT00283335: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT00283335 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 2,531 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (228% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00283335, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,531 participants
- Enrollment target
Study Summary
This was a double-blind randomized trial comparing 1200 mg per day of gemfibrozil with placebo in 2531 men with coronary heart disease, an HDL-C of 40mg/dl or less, an LDL-C of 140 mg/dl or less, and triglycerides of 300mg/dl or less. The primary outcome was nonfatal myocardial infarction(MI) or death from coronary causes. The median follow-up was 5.1 years. There was a risk reduction of 22% in the primary outcome (p=.0006) and 24% risk reduction in the combined endpoint of stroke, MI, and CHD death. The rate of events was reduced by raising HDL-C and lowering triglycerides without lowering LDL-C (N Engl J Med 1999;341:410-418).
Interventions
- OTHER Placebo
- DRUG gemfibrozil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,531 participants |
| Start Date | 1991-06 |
| Est. Completion | 1999-08 |
| Phase | Phase 3 |
What the finished NCT00283335 record still lists
NCT00283335 is an interventional study that assigns participants to a tested intervention. Its 2,531 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (228% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00283335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00283335 about?
NCT00283335 is a clinical study titled "The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol". This was a double-blind randomized trial comparing 1200 mg per day of gemfibrozil with placebo in 2531 men with coronary heart disease, an HDL-C of 40mg/dl or less, an LDL-C of 140 mg/dl or less, and triglycerides of 300mg/dl or less. The primary outcome was nonfatal myocardial infarction(MI) or dea...
What is the current status of trial NCT00283335?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,531 participants. The study started on 1991-06. Estimated completion is 1999-08.
What interventions are being tested in trial NCT00283335?
The interventions under investigation include: Placebo (OTHER), gemfibrozil (DRUG).
Who is sponsoring clinical trial NCT00283335?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00283335's enrollment target sits among peer trials
2,531 87th of 2000 higher than 1,914 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia